- In March 2025, Cambridge Isotope Laboratories announced the expansion of its European production facilities to meet the rising demand for stable isotope-labeled compounds in pharmaceutical and research sectors. This expansion is expected to enhance supply capabilities and support ongoing drug development initiatives.
- In April 2025, Merck KGaA launched a new line of high-purity stable isotope-labeled compounds designed for advanced metabolic and pharmacokinetic studies. The launch aims to strengthen Merck’s presence in Europe’s pharmaceutical research market.
- In February 2025, IsoSciences opened a new research center in Germany focused on developing sustainable isotope labeling technologies. The facility will drive innovation and reduce environmental impact in stable isotope production.
- In January 2025, TAIYO NIPPON SANSO CORPORATION partnered with leading European biotech firms to supply stable isotope-labeled compounds for precision medicine applications. This collaboration is expected to accelerate clinical research across Europe.
- In May 2025, PerkinElmer Inc. announced investment plans to upgrade its isotope labeling production line in the UK, increasing capacity to meet growing demand from pharmaceutical and biopharmaceutical companies focused on next-generation drug development.
